Modulation of PIP₂ levels by PLC activity in INS-1 and RyR2^KO cells. by Kyle E. Harvey (4375987)

“…INS-1 cells: n = 1294; RyR2^KO cells: n = 1377; IRBIT^KO cells n = 1650. Data are shown as mean ±SD. One-way ANOVA with Dunnett’s multiple comparisons test. …”

Ablation of <i>PC3/Tis21</i> impairs terminal differentiation of 1- to 5-day-old adult-generated dentate gyrus progenitor cells. by Stefano Farioli-Vecchioli (256006)

“…Scale bar, 50 µm; 27 µm in the inset.</p>…”

All-atom molecular dynamics simulation of peptides by Ning Zhu (10901010)

PLK2i treatment of OHSCs does not affect generation of pS129 positive aggregates, but reduces the nuclear pS129 intensity. by Sara Elfarrash (8159490)

“…Scale bars = 20 μm. b) Quantification of the amount of aggregation (aggregate area normalized to tissue area), defined by MJF-14 staining (p-value = 0.09). c-d) Quantification of the mean fluorescence intensity of α-syn aggregates detected with MJF-14 (c, p-value = 0.712) and aggregate-specific pS129 that overlaps with MJF-14 (d, p-value = 0.214). e) Quantification of nuclear (non-aggregate related) pS129, illustrating a significant decrease in mean fluorescence intensity following PLK2i-treatment (p-value = 0.0087). f) Relative ratio of aggregate-specific pS129/nuclear pS129 in PFF-injected slices shows an increase of ratio of the signals of aggregates/background following PLK2i treatment, due to reduction of the non-aggregate-related nuclear pS129-signal (p-value = 0.009). …”

Healthcare resource use and direct costs in severe aplastic anemia (SAA) patients before and after treatment with eltrombopag by Beilei Cai (3588746)

“…</p> <p><b>Results:</b> The average patient age was 50.8 (<i>SD</i> = 20.6) years old, predominantly female (<i>n</i> = 43, 52.4%), and had a mean CCI at baseline of 1.1 (<i>SD</i> = 1.7). …”

Mucin deglycosylase activity of ChiA2. by Moumita Mondal (632557)

“…This shows the graphical representation of % area density of the alcian blue stained spots (the above picture) of control, ChiA2-untreated and treated rabbit mucin respectively (from left). A 50-fold decrease in the % area density of the spot was observed for ChiA2-treated rabbit mucin compared to the untreated one. …”

γδ T cells have similar TCR threshold but enhanced ERK1/2 phosphorylation comparing to αβ T cells. by Hsin-Yuan Cheng (414160)

“…Results were averaged from 7–8 mice, and shown in mean ± SEM. ** P<0.01; *** P<0.001; ns not statistically significant.…”

Glycogen synthase knockdown inhibits autophagosome growth and improves CQ-induced myopathy phenotype. by Jonathan Zirin (483506)

Alpha band (6 by Dirk J. A. Smit (109730)

“…Overall connectivity significantly increased up to ∼40 but peaked at ∼50, and showed a significant decrease into older age (55+).…”

FIGURE 1 from Immunologic Signatures of Peripheral Blood T Cells Reveal the Outcome of p53MVA Vaccine and Pembrolizumab Treatment in Patients with Advanced Ovarian Cancer by Ferdynand J. Kos (17683564)

“…Relative changes in tumor sizes derived from radiological evaluations (<b>A</b>) show that 3/28 PR patients had a decrease of 76.4%, 93.3%, and 59.5% in tumor burden (irRECIST). …”

Incidence of total ventilator-associated pneumonia (VAP) during different study periods. by Kang-Cheng Su (3914384)

A reliable and cost-effective planning framework of rural area hybrid system considering intelligent weather forecasting by Abazari, A.

“…Consequently, for LPSPmax=10% and REPmin=91%, and 50% rise in the price of fuel, the number of DEG drops to zero, and the optimal number of PV and BESS increase from 311 and 172 to 411 and 228, respectively.…”
Get full text
Get full text

Test scores and ordering costs. by Jinghong Ma (1755838)

Influence of UGT2B10 Genotype on Urinary Excretion of 4‑(Methylnitrosamino)-1-(3-pyridyl)-1-butanol-<i>N-</i>glucuronide by African American Smokers by Sharon E. Murphy (272512)

“…In this study, the excretion of total NNAL (free plus glucuronides) by African American (<i>n</i> = 52) and white (<i>n</i> = 54) smokers was not different; however, total NNAL glucuronidation by African Americans (64.0%) was slightly less than by whites (68.3%, <i>p</i> = 0.05). The mean NNAL-<i>N</i>-glucuronidation by African Americans was much lower than for whites (14 vs 24.9%, <i>p</i> < 0.00001), but the NNAL-<i>O</i>-glucuronidation was greater (50.0 vs 43.3%, <i>p</i> = 0.013). …”

Effect of on Bepridil on APP processing. by Kamran Honarnejad (485648)

“…(n.s.: non-significant; * P<0.05, ** P<0.01 and *** P<0.001).…”

The funnel plot of visual analog scale score. by Guimei Guo (4127074)

“…The PRP also showed a decrease in VAS score compared to baseline than the non-PRP at 3 months (MD = -0.29, 95% Cl: -0.41 to -0.17, P = 0.003), 6 months (MD = -0.63, 95% Cl: -0.96 to -0.30, P = 0.0002), 12 months (MD = -0.78, 95% Cl: -1.22 to -0.33, P = 0.0006), ≥ 24 months (MD = -1.11, 95% Cl: -1.27 to -0.96, P < 0.00001), and the last follow-up (MD = -0.74, 95% Cl: -1.05 to -0.43, P < 0.00001). …”

Intervention characteristics of included studies. by Guimei Guo (4127074)

“…The PRP also showed a decrease in VAS score compared to baseline than the non-PRP at 3 months (MD = -0.29, 95% Cl: -0.41 to -0.17, P = 0.003), 6 months (MD = -0.63, 95% Cl: -0.96 to -0.30, P = 0.0002), 12 months (MD = -0.78, 95% Cl: -1.22 to -0.33, P = 0.0006), ≥ 24 months (MD = -1.11, 95% Cl: -1.27 to -0.96, P < 0.00001), and the last follow-up (MD = -0.74, 95% Cl: -1.05 to -0.43, P < 0.00001). …”

GRADE evaluation of evidence quality. by Guimei Guo (4127074)

“…The PRP also showed a decrease in VAS score compared to baseline than the non-PRP at 3 months (MD = -0.29, 95% Cl: -0.41 to -0.17, P = 0.003), 6 months (MD = -0.63, 95% Cl: -0.96 to -0.30, P = 0.0002), 12 months (MD = -0.78, 95% Cl: -1.22 to -0.33, P = 0.0006), ≥ 24 months (MD = -1.11, 95% Cl: -1.27 to -0.96, P < 0.00001), and the last follow-up (MD = -0.74, 95% Cl: -1.05 to -0.43, P < 0.00001). …”

PRISMA flow diagram. by Guimei Guo (4127074)

“…The PRP also showed a decrease in VAS score compared to baseline than the non-PRP at 3 months (MD = -0.29, 95% Cl: -0.41 to -0.17, P = 0.003), 6 months (MD = -0.63, 95% Cl: -0.96 to -0.30, P = 0.0002), 12 months (MD = -0.78, 95% Cl: -1.22 to -0.33, P = 0.0006), ≥ 24 months (MD = -1.11, 95% Cl: -1.27 to -0.96, P < 0.00001), and the last follow-up (MD = -0.74, 95% Cl: -1.05 to -0.43, P < 0.00001). …”

Summary data and analyses. by Guimei Guo (4127074)

“…The PRP also showed a decrease in VAS score compared to baseline than the non-PRP at 3 months (MD = -0.29, 95% Cl: -0.41 to -0.17, P = 0.003), 6 months (MD = -0.63, 95% Cl: -0.96 to -0.30, P = 0.0002), 12 months (MD = -0.78, 95% Cl: -1.22 to -0.33, P = 0.0006), ≥ 24 months (MD = -1.11, 95% Cl: -1.27 to -0.96, P < 0.00001), and the last follow-up (MD = -0.74, 95% Cl: -1.05 to -0.43, P < 0.00001). …”